Last December, Adagrasib (KRAZATI) received approval by the FDA as an oral second-line drug for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in adults.

It is a specific, irreversible inhibitor of  KRAS harboring G12C mutation. KRAS is the most commonly mutated isoform of RAS in cancer, including 85% of oncogenic RAS mutations. In the case of NSCLC, KRAS has mutated in around one-third of patients.

Adagrasib has a warhead that permanently binds to the target.

We offer you 40 Covalent Modifiers sets with versatile binders , including in-stock Cysteine- and Lysine-targeted ligands which could be the perfect start for your research in anti-cancer and others medications!